Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Japan Selects JN.1 Substrains for COVID Vaccines in 2025-2026 Season
A Japanese health ministry panel on May 28 agreed to adopt “descendent lineages of the JN.1 strain” for the antigen composition of the COVID-19 vaccine to be used in the national immunization program in the 2025/2026 season. The decision was…
To read the full story
Related Article
- Moderna Launches LP.8.1-Adapted Spikevax for Ages 6 Months to 11 Years
October 15, 2025
- Moderna Rolls Out LP.8.1-Tailored Spikevax in Japan
September 24, 2025
- Japan Panel Approves 5 COVID Vaccines for NIP Use from October
September 9, 2025
- Japan Approves Pfizer/BioNTech’s LP.8.1-Tailored COVID Vaccines
August 12, 2025
- Japan Approves Updated Spikevax for LP.8.1 Omicron Strain
August 6, 2025
- Moderna Japan Files Updated COVID Shot for Age 11 and Under
June 30, 2025
- LP.8.1-Adapted Novavax COVID Vaccine Filed in Japan: Takeda
June 30, 2025
- Moderna Files Updated Spikevax for LP.8.1 Strain in Japan
June 9, 2025
REGULATORY
- LDP Panel Delays Approval of Health Insurance Bill amid Concerns over OTC-Like Drug Charges
February 26, 2026
- Takaichi Signals Continued Off-Year Revisions despite Abolition Calls
February 26, 2026
- Symbicort Switch to OTC Status Gains No Support at MHLW Panel
February 25, 2026
- Japan Govt Council Finalizes Recommendations for National MCM Strategy
February 25, 2026
- Japan Panel to Review Haihe’s PI3Kα Inhibitor, MSD’s HIV Med, and More on March 2
February 24, 2026
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Following Hisamitsu Pharmaceutical’s decision to go private through a roughly 400 billion yen management buyout (MBO), industry observers are weighing…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…